All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
The HALT Study
A Prospective Multicenter Single-arm Staged Study to Evaluate the Safety and Effectiveness of Embrace™ Hydrogel Embolic For Transcatheter Embolization of Arterial Bleeding in Solid Organs and Peripheral Arteries (Instylla, Inc.)
OCS Heart Perfusion Post-Approval Registry
The Organ Care System (OCS) Heart Perfusion Post-Approval Registry (OHP)
The objective of this post-approval registry is to provide additional real-world evidence of the performance of the OCS Heart System to preserve donor-after-brain-death (DBD) and donation-after-circulatory-death (DCD) donor hearts.
CentriMAG Failure to Wean Post Approval Study
As part of heart surgery, patients are put on cardiopulmonary bypass, a machine that temporarily takes over the function of the heart and lungs during surgery, maintaining circulation of blood and oxygen to the rest of the body. In some cases, patients are not able to get off bypass, and their heart is not able to spontaneously contract to allow for normal blood circulation. The CentriMag Circulatory Support System provides support to these patients, if needed. The CentriMag system, supports the heart and moves blood through the circulatory system until the patient’s heart recovers, is transplanted, or needs long term mechanical circulatory support. The purpose of this research study is to continue monitoring and collecting data for patients who require the CentriMag Circulatory Support System. The CentriMag Circulatory Support System has been approved by the FDA and is currently in commercial use. It is therefore not an investigational device. This study is required by the FDA for continued data collection for patients who are implanted with the device for up to 30 days post-explant or discharge, whichever time point is longer. If you are not able to be taken off the device, follow-up will last until start of anesthesia for another medical intervention (a heart transplant or long-term device).
OCS™ Lung TOP Registry For Donor Lungs for Transplantation
The Organ Care System (OCS™) Lung Thoracic Organ Perfusion (TOP) Registry For Donor Lungs for Transplantation
The purpose of this project is to monitor the performance of the OCS™ Lung System and to collect additional clinical data from patients transplanted with donor lungs preserved using the TransMedics OCS™ Lung System for preservation of donor lungs for transplantation.
Impella Supported OPCABG
Impella-Supported Off-pump Coronary Artery Bypass Grafting in High-Risk Revascularizations: A Single Center Prospective Observational Study
STRIKE-PE
A Prospective, Multicenter Study of the Indigo™ Aspiration System Seeking to Evaluate the Long-Term Safety and Outcomes of Treating Pulmonary Embolism
ACURATE IDE
Transcatheter Replacement of Stenotic Aortic Valve through Implantation of ACURATE in Subjects InDicatEd for TAVR
To evaluate safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for transcatheter aortic valve replacement (TAVR) in subjects with severe native aortic stenosis who are indicated for TAVR.
CLASP II TR Pivotal Trial (PASCAL)
Edwards PASCAL TrAnScatheter Valve RePair System Pivotal Clinical Trial (CLASP II TR)
This trial is designed as a multicenter, randomized, controlled pivotal trial to compare the safety and effectiveness of the PASCAL System and optimal medical therapy to optimal medical therapy alone for patients with tricuspid regurgitation.
Tendyne SUMMIT
This is a clinical trial to evaluate the safety and effectiveness of using the Tendyne Mitral Valve System for the treatment of symptomatic mitral regurgitation compared to the MitraClip System.
CATALYST
Clinical trial of atrial fibrillation patients comparing left atrial appendage occlusion therapy to non-vitamin K antagonist oral anticoagulants
The CATALYST Trial will compare treatment with Abbott’s Amplatzer™ Amulet™ Left Atrial Appendage Occluder to treatment with non-vitamin K antagonist oral anticoagulants (NOACs) in patients with non-valvular atrial fibrillation at high-risk for stroke.
PATH-HHT
Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia
The purpose of this study is to determine efficacy of pomalidomide compared to placebo for the reduction in severity of epistaxis after 24 weeks of treatment.
ECMOCARD
ExtraCorporeal Membrane Oxygenation for 2019 Novel Coronavirus Acute Respiratory Disease
The purpose of this study is to describe clinical features; severity of pulmonary dysfunction; incidence of ICU admission and use of mechanical ventilation and ECMO; ECMO technical characteristics; duration of ECMO; complications; and survival of patients with COVID-19.
Evaluation of Hemodynamic Parameters Following Transjugular Intrahepatic Portosystemic Shunt (TIPS)
This study is being done to determine the impact of the TIPS procedure on cardiac (heart) function by collecting data (heart pressures) during the IPS procedure. Immediately after TIPS and at standard follow-up time points, labs and transthoracic echocardiograms (TTE or echo) will also be collected.
The C-TRACT Trial
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy
Determine if the use of imaging-guided endovascular therapy (EVT) is an effective strategy with which to reduce Post-Thrombotic (PTS) disease severity and improve quality of life (QOL) in patients with established disabling iliac-obstructive post-thrombotic syndrome (DIO-PTS).
Effect of Probiotic Supplementation on Endothelial Function
To determine whether daily supplementation with the probiotic Lactobacillus plantarum 299v improves the function of blood vessels in patients with coronary artery disease.
MINT
Myocardial Ischemia and Transfusion
The purpose of this study is to assess among patients with an acute myocardial infarction and a hemoglobin concentration less than 10 g/dL, if a liberal transfusion strategy with a threshold of 10 g/dL reduces the rate of the composite outcome of all-cause mortality or recurrent nonfatal acute myocardial infarction through 30 days following randomization compared to a restrictive transfusion strategy with a threshold of 7 to 8 g/dL.